Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy

Objective Immune-mediated necrotizing myopathies (IMNMs) are severe forms of myositis often associated with pathogenic anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies (aAbs). Efgartigimod is an engineered human IgG1 Fc fragment that antagonizes the neonatal Fc receptor (FcRn), thereby preventing recycling and promoting lysosomal degradation of IgG, including aAbs. We evaluated the therapeutic effects of IgG reduction by efgartigimod in a humanized murine model of IMNM. Methods Disease was induced in C5-deficient (C5(def)) or Rag2-deficient (Rag2(-/-)) mice receiving co-injections of anti-HMGCR(+) IgG from an IMNM patient and human complement. C5(def) mice were treated in a preventive setting with s.c. injections of efgartigimod and Rag2(-/-) mice in a curative setting after disease was induced by anti-HMGCR(+) IgG injections. Anti-HMGCR aAbs levels were monitored in mouse serum and muscle tissue. Histological analysis was performed on muscle sections. Muscle force was assessed by grip test or measurement of gastrocnemius strength upon electrostimulation. Results Administration of efgartigimod rapidly reduced total IgG levels, including the level of pathogenic anti-HMGCR aAbs, in both serum (P < 0.0001) and muscle (P < 0.001). In the preventive setting, efgartigimod prevented myofibre necrosis (P < 0.05), thus precluding loss of muscle strength (P < 0.05). In the therapeutic setting, efgartigimod prevented further necrosis and allowed muscle fibre regeneration (P < 0.05). Hence, muscle strength returned to normal (P < 0.01). Conclusion Efgartigimod reduces circulating IgG levels, including pathogenic anti-HMGCR(+) IgG aAbs, in a humanized mouse model of IMNM, preventing further necrosis and allowing muscle fibre regeneration. These results support investigating the therapeutic efficacy of efgartigimod through a clinical trial in IMNM patients.

Automated summary

In this study, the therapeutic effects of efgartigimod in immune-mediated necrotizing myopathies were evaluated using a humanized murine model. The results showed that efgartigimod rapidly reduced total IgG levels and prevented myofibre necrosis, allowing muscle fibre regeneration.